Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Lucrative Positions in the Advancing Position Market of 2024 - 2Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- 3Courageous Climbing: Trails and Stuff for Outside Lovers
- 4A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- 5A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Fact Check: Some Bridge Photos Circulating Do NOT Show The Hongqi Bridge That Collapsed In Southwest China Nov. 11, 2025
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- Figure out How to Pick a Crematorium: Key Contemplations.
- Bennu asteroid samples provide clues about solar system origins and 'space gum'
- Japanese H3 rocket fails during launch of navigation satellite (video)
- UN estimates over 2,000 Sudanese pregnant women have fled el-Fasher to escape conflict
